Advanced C2 Cryoballoon Ablation System Introduced By Pentax Medical for Treating Barretts Esophagus

PENTAX Medical Company, a pioneer in the healthcare sector in therapeutic and diagnostic endoscopy, reports the advent of the C2 CryoBalloonTM Ablation System for the treatment of Barrett's esophagus, a condition in which the coating of the esophagus creates abnormal injuries fundamentally because of endless gastroesophageal reflux disease (GERD). An anticipated 3.3 million individuals in the U.S. are living with Barrett's esophagus, which influences an individual 30 to 40 to times more prone to have esophageal cancer – an illness with a 19.2% five-year rate of survival. PENTAX Medical will highlight the cutting edge endoscopic cryoablation device at Digestive Disease Week® (DDW) in Washington, DC from June 2– 5. DDW is the biggest gathering of doctors, academics and researchers internationally in the fields of endoscopy, hepatology, gastroenterology and gastrointestinal surgery. Independently, the organization reported that starting June 1, the engineer of the C2 CryoBalloon, C2 Therapeutics, which it acquired a year ago, will work under the PENTAX Medical name. The C2 CryoBalloon Ablation System is useful to damage undesirable tissue by use of extreme cold. A balloon inquest, which is attached to a catheter, interacts with the wall of the objective tissue.

Upon actuation by a doctor, the balloon test is at the same time cooled and inflated with nitrous oxide. The extreme cold destroys the focused on precancerous or irregular lesions along the lining of the esophagus while at the same time saving healthy tissue. The system permits doctors total control of the system under direct perception of the treatment area amid the process, which keeps going between 15 to 30 minutes. The new C2 CryoBalloon Ablation System provides certain benefits including the capacity to ablate an extensive variety of patients, upgraded visualization and control, and another level of effectiveness. MD, FACG, FASGE, Clinical Associate Professor of Medicine of the Geisinger Medical Center Harshit S. Khara affirms that with the help of the C2 Cryoballoon, practices can be enhanced as a more exhaustive Barrett's center with the most recent and best treatment choices. As per clinical investigations, 95 percent of patients treated with the C2 CryoBalloon accomplish complete destruction of dysplasia (CED) and 90 percent have complete eradication of intestinal metaplasia (CEIM) through two years. Moreover, multi week following treatment, no patients needed narcotic pain medication.